Quick Answer: Tirzepatide is not approved for autoimmune disease treatment and has no established clinical evidence demonstrating efficacy for these conditions
The lack of statistically significant reduction in infarct volume, despite a numerical decrease, suggests that DSIPs primary benefit in this model might be more related to functional neurorecovery and neural network plasticity rather than a direct, massive reduction of necrotic tissue [1]
Further, kinetic studies of seleno-GPxs have revealed that the rate constant for the reaction of hydroperoxides with the selenolate of Sec is twothree orders of magnitude higher than the combined rate constant of the successive reactions of selenenic acid with the two molecules of GSH [8,9,10,11,12,13,14,15,16,17,18]
SG and WZ supported, edited, and revised the work
Peak is injections only